Introduction {#sec1}
============

Bronchiectasis (BE) is a chronic inflammatory lung disease that leads to persistent productive cough, recurrent lower respiratory tract infections, and obstructive lung disease in children and adults \[[@cit0001]\]. The disease is characterised by abnormal and persistent dilatation of the airways, which occurs as a result of the chronic inflammation due to insufficient mucosal clearance and recurrent/chronic infections of the airways \[[@cit0002]\]. The exacerbations observed in BE patients, reduce lung function by increasing the damage in the lung parenchyma, impair quality of life and lead to the development of respiratory failure in patients \[[@cit0003]\]. In BE patients, identification of biomarkers of inflammation showing relapse is of great importance. Most of the present biomarkers require cooperation of the patient or tend to be invasive, therefore they cannot be used effectively. For example, the spirometric measurements that are often used require effective cooperation and thus have limited use in small children, and methods such as bronchial biopsy and bronchoalveolar lavage (BAL) are not practical because they tend to be invasive \[[@cit0004], [@cit0005]\].

Neutrophils and platelets are known to be engaged in the inflammatory process in BE and to play a role in progressive lung damage \[[@cit0001]-[@cit0003]\]. Mean platelet volume (MPV) is a value that indicates platelet activation, and can be used as a biomarker in inflammation \[[@cit0006]-[@cit0008]\]. Also in adult studies, it has been shown that the neutrophil-to-lymphocyte ratio (NLR) may be a biomarker of airway inflammation \[[@cit0009]\].

The aim of our study is to investigate the potential of MPV and NLR as biomarkers that may indicate acute exacerbations of non-cystic fibrosis (CF) BE in children.

Material and methods {#sec2}
====================

Patient population {#sec2.1}
------------------

All patients who had a diagnosis of non-CF BE or were hospitalised due to acute exacerbation between June 2010 and July 2015, were included in the present retrospective cross-sectional study. Average age of the 50 children who were hospitalised due to acute exacerbation was detected as 151 (±53 SD) months. Twenty-four (48%) were male and 26 (52%) were female. In the control group, 45 (51.7%) were male, 42 (48.3%) were female, and the average age was 150 (±36 SD) months. The diagnosis was confirmed by thorax High-Resolution Computed Tomography (HRCT) in the patients who had a persistent wet cough and abnormal chest X-ray findings that did not respond to antibiotic therapy and also maintained non-regressive symptoms for 2-4 weeks \[[@cit0010]\]. The aetiology of BE was detected as; primary immune deficiency 26%, protracted bacterial bronchitis 22%, bronchiolitis obliterans 18%, primary ciliary dyskinesia 10%, lung disease secondary to gastro-oesophageal reflux 8%, foreign body aspiration 6%, tuberculosis 6%, and congenital malformation 4%. Exacerbation criteria were defined as having more than two of the following signs and symptoms: increase in cough frequency, sputum production with changes in sputum content, dyspnoea, tachypnoea, reduced exercise capacity, loss of appetite, haemoptysis, fever above 38^o^C, and clinically determined crackles and wheezing \[[@cit0010]\]. Children who were diagnosed with sepsis, iron deficiency anaemia, obesity, hyperlipidaemia, diabetes mellitus, hypertension, chronic renal failure, nephrotic syndrome, inflammatory bowel disease, connective tissue disease, or receiving systemic steroids within the last month were excluded from our study because it was previously reported that these diseases affected MPV and NLR values. The demographic parameters of patients and haemogram findings in non-exacerbation periods were obtained from the file records. When patients were hospitalised due to acute exacerbation, full blood count and C-reactive protein (CRP) were studied. Haemogram parameters and CRP values in acute exacerbations (Group 1) and non-exacerbation periods (Group 2) were compared. Eighty-seven healthy children with equivalent age and gender were randomised as the control group. Then the same parameters were compared with the data of the patients in the healthy control group (Group 3). Approval by the local Ethics Committee was granted.

Counting blood samples {#sec2.2}
----------------------

Whole blood count was performed via Beckman Coulter LH 780, and blood samples which were anticoagulated with K3EDTA were used. The Coulter principle is volumetric analysis. Haemoglobin level, white blood cell count (WBC), platelet count, and MPV values were recorded for each patient. The reference range for MPV was between 7.0 and 11.0 fL. The neutrophil-lymphocyte ratio was calculated by dividing the percentage of neutrophils and lymphocytes in complete blood count analysis. Serum CRP level was measured using an Abbott c8000 Architect (USA) device.

Statistical analyses {#sec2.3}
--------------------

Statistical Package for Social Sciences (SPSS for Windows 15.0 Chicago, USA) software was used to analyse the data. Results were given as either mean ± standard deviation (SD) or median (min-max) according to the distribution. The Chi-squared test was used to compare grouped data. The paired *t*-test was used to compare group-specific measurements, and the independent Student's *t*-test to compare measurements among independent groups. Kruskal-Wallis test and Mann-Whitney *U* tests were used for non-normally distributed variables. Pearson's correlation analysis was used to explore correlations between the measurements. *P*-values \< 0.05 were considered statistically significant.

Results {#sec3}
=======

Leukocyte count, platelet count, MPV, neutrophil count, absolute lymphocyte count, and NLR values of patients during acute exacerbations and non-exacerbation periods and of control group are shown in [Table 1](#t0001){ref-type="table"}. Platelet counts of both acute exacerbations and non-exacerbation periods were significantly higher than those in the control group (*p* = 0.001, *p* = 0.018). Average MPV values of non-exacerbation periods were significantly higher than in the control group (*p* = 0.03). In contrast, the MPV values of acute exacerbation were not statistically different when compared to non-exacerbation periods or the control group (*p* = 0.103, *p* = 0.530, respectively) ([Table 1](#t0001){ref-type="table"}).

###### 

Comparison of haemogram parameters and C-reactive protein levels between acute exacerbation (Group 1), non-exacerbation (Group 2), and controls (Group 3)

  Parameter                                Group 1 (*n* = 50)   Group 2 (*n* = 50)   Group 3 (*n* = 87)   1-2 *p*    2-3 *p*    1-3 *p*
  ---------------------------------------- -------------------- -------------------- -------------------- ---------- ---------- ----------
  WBC (× 10^3^/μl)                         10.8 ±4.1            8.5 ±3.5             7.3 ±1.4             0.83       \< 0.001   \< 0.001
  Absolute neutrophil count (× 10^3^/μl)   7.3 ±4.1             4.9 ±3.1             3.8 ±1.1             0.001      \< 0.001   \< 0.001
  Absolute lymphocyte count (× 10^3^/μl)   2.1 ±0.8             2.4 ±0.9             2.7 ±0.6             0.71       0.607      \< 0.001
  NLR                                      5.1 ±6.3             2.3 ±2.2             1.5 ±1.2             0.02       0.01       \< 0.001
  CRP (mg/l)                               4.1 ±7.0             0.45 ±0.5                                 \< 0.001   \-         \-
  Plt (× 10^3^/μl)                         319 ±103             336 ±106             285 ±62              0.284      0.001      0.018
  MPV (fl)                                 8.5 ±0.9             8.6 ±1.09            8.2 ±0.7             0.530      0.03       0.103

WBC -- white blood cell, NLR -- neutrophil-to-lymphocyte ratio, CRP -- C-reactive protein, Plt -- platelet, MPV -- mean platelet volume Data are shown as means ± standard deviation for normally distributed variables

Absolute neutrophil counts in the periods of acute exacerbations and non-exacerbation were significantly higher than in the control group (*p* \< 0.001). When periods of acute exacerbations and non-exacerbation were compared, absolute neutrophil count was found to be significantly higher in the period of exacerbation (*p* = 0.001) ([Table1](#t0001){ref-type="table"}). NLR revealed a statistically significant increase both in the period of acute exacerbation and during non-exacerbation when compared with the control group (*p* = 0.02, *p* = 0.01). Also, when compared to each other, NLR in the exacerbation period was significantly higher than during the period of non-exacerbation (*p* \< 0.001) ([Table 1](#t0001){ref-type="table"}). The CRP values in the acute exacerbation period were significantly higher than in the non-exacerbation period (*p* \< 0.001) ([Table 1](#t0001){ref-type="table"}). We investigated the correlation between leukocyte count and CRP values with the MPV. When acute exacerbations and non- exacerbation periods were compared, there was no correlation. A moderately (*r* = 0.498) significant, positive correlation was found between NLR and acute exacerbation period CRP levels (*p* \< 0.001). Similarly, a moderately (*r* = 0.663) significant positive correlation was found between NLR and acute exacerbation-period leucocyte numbers (*p* \< 0.001) ([Table 2](#t0002){ref-type="table"}).

###### 

Correlation of neutrophil count and C-reactive protein levels and correlation of mean platelet volume and neutrophil-to-lymphocyte ratio in patient groups during acute exacerbation and non-exacerbation chronic disease periods

  Factor                             MPV (fl)   NLR             
  ---------------------------------- ---------- ------- ------- ----------
  The period of acute exacerbation                              
   CRP (mg/l)                        0.01       0.947   0.498   \< 0.001
   WBC (× 10^3^/l)                   --0.033    0.704   0.663   \< 0.001
  The period of chronic illness                                 
   CRP (mg/l)                        0.041      0.777   0.033   0.819
   WBC (× 10^3^/l)                   --0.029    0.841   0.441   0.001

CRP -- C-reactive protein, WBC -- white blood cell, MPV -- mean platelet volume, NLR -- neutrophil-to-lymphocyte ratio Pearson correlation analysis

Discussion {#sec4}
==========

In the present study, which evaluates the potential of haemogram parameters of children with BE (especially MPV and NLR) as biomarkers of acute exacerbation, it was detected that 1) leukocyte count, platelet count, absolute neutrophil count, and NLR show chronic inflammation of BE, and 2) only absolute neutrophil count and NLR can be used as biomarkers of acute exacerbation. To the best of our knowledge, there is no study in the literature that evaluates the roles of both MPV and NLR in predicting acute exacerbation in patients with BE.

Mean platelet volume is correlated with platelet function and activation \[[@cit0006]\]. Platelet activation that occurs in the process of inflammation can be measured indirectly through MPV. Mean platelet volume alone represents both platelet stimulation and the rate of platelet production \[[@cit0011]\]. CD62, CD63, GP IIB/IIIA, PF4, and thromboglobulin can be used as markers of platelet activation \[[@cit0012]\]. These tests are not routinely used due to their high cost and need of specialised equipment \[[@cit0013]\]. Measurement of mean platelet volume is a cheap, effective, and an easy method that is closely correlated with platelet function and activation and is used in the assessment of platelet function.

Recent studies show that platelets, one of the most important elements of the haemostasis process, also play a role in the development of immune response \[[@cit0014]\]. Usually in adult studies, it has been shown that there is platelet activation in different inflammatory lung diseases \[[@cit0008], [@cit0009], [@cit0015]-[@cit0021]\]. In the study by Bansal *et al*. \[[@cit0015]\] involving 100 patients with chronic obstructive pulmonary disease (COPD) and 100 healthy subjects, the MPV values in COPD patients were detected as being higher than those in the control group. Erden *et al*. \[[@cit0016]\] found MPV values to be higher during flare-up periods in their work about exacerbation of COPD. In another study with 85 COPD patients, MPV values and the number of leukocytes were found to be significantly higher in COPD patients compared to the control group \[[@cit0017]\]. In contrast, in the study of Uysal *et al*. \[[@cit0018]\] evaluating children with BE, MPV levels in the acute exacerbation period were found to be significantly lower when compared to the non-exacerbation period and the control group. In asthmatic children, as another chronic airway disease, Tuncel *et al*. \[[@cit0019]\] did not find any difference between MPV levels of acute episodes and symptom-free periods. Similarly, in our study about children with asthma, there were no difference between MPV values in acute episodes and symptom-free periods \[[@cit0020]\]. As seen in the literature, different conclusions concerning use of MPV as a marker of inflammation are reported. In our study, no statistical difference was detected between MPV levels of acute exacerbation periods and non-exacerbation periods, so it can be concluded that MPV cannot be used as a marker for exacerbation. Different results in various studies may result from methodological changes. Also, MPV levels may be influenced by the method of blood sampling, care of blood samples, time between sampling and analysing, and the drugs used by the cases \[[@cit0018]\]. In our study, platelet counts in the acute exacerbation and non-exacerbation periods were significantly higher than in the control group. This result leads to the idea that increased platelet count is associated with chronic inflammation in BE, but measurement of MPV is not adequate for showing inflammation via platelets in cases of acute exacerbation.

NLR has been used as a marker for inflammation in several diseases because the physiological responses of circulating leucocytes in the human body to stress are an increase in the number of neutrophils and a decrease in the number of lymphocytes \[[@cit0021], [@cit0022]\]. In various studies about NLR, many domains such as systemic oxidative stress, activation of circulating inflammatory cells, an increase in plasma cytokines and acute phase proteins, weight loss, and skeletal muscle dysfunction are observed related to the inflammatory response in the lungs \[[@cit0009], [@cit0023]-[@cit0028]\]. Related to this, in studies of adult patients with COPD, significant rises in serum CRP levels and leukocyte counts in the period of acute exacerbation of COPD have been shown \[[@cit0023]-[@cit0025]\]. Drews *et al*. \[[@cit0026]\] showed an increase in sputum eosinophil counts in the majority of children with atopic asthma, and in contrast, a significantly higher sputum neutrophil rate in nonatopic children with asthma. Zhang *et al*. \[[@cit0027]\], in a study evaluating the blood cell counts and the percentages of neutrophils and eosinophils in sputum cytology in asthmatic patients, detected an increase of NLR in neutrophilic asthma and reported this finding to be a practical parameter especially in uncontrolled asthma. Furukawa *et al*. \[[@cit0028]\] showed that the number of neutrophils in sputum were increased in asthmatic children, and there is a small correlation between the NLR of the patients with the number of hospital admissions. In a study of 50 adult patients with asthma, Fu *et al*. \[[@cit0029]\] found that the number of neutrophils in the sputum is higher in asthmatic patients with systemic inflammation. Gunay *et al*. \[[@cit0030]\], in a study on 269 patients with COPD, showed that NLR were higher than controls in patients with stable COPD, and there is a positive relationship between CRP and NLR. Similarly, in our study, leukocyte count, absolute neutrophil count, NLR, and CRP values in children with BE were higher when compared to the control group. Also, a moderate positive correlation between NLR and CRP, with leukocyte count, was detected. Therefore, we think that NLR could be used as a marker to show acute exacerbation.

The limitations of our study are the insufficient number of patients and its retrospective nature. Thus, the effects of respiratory function tests in acute exacerbations and non-exacerbation periods, sputum cytology, colonisation status on NRL, and MPV could not be studied. We think that correlation analysis with proinflammatory cytokines, which has been shown to play a role in the inflammation process of acute exacerbation and progressive period of BE patients, such as IL-6, IL-8, TNF-α, and ICAM, should be done in subsequent studies.

As a result of this study, it can be concluded that there may be a role played by platelets in the pathophysiology of BE, but MPV measurement is not a potential biomarker of acute exacerbations. In contrast, NLR and absolute neutrophil count, as a quick, cheap, and easily measurable feature, can be used as a marker for acute exacerbations of BE in children.
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